ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1408

In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study

Reinder Raadsen1, Rabia Agca2, Maarten Boers3, Vokko van Halm2, Mike Peters4, Yvo Smulders2, Joline Beulens2, Marieke Blom2, Coen Stehouwer5, Alexandre Voskuyl2, Willem Lems6 and Michael Nurmohamed7, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 4Amsterdam UMC; UMC Utrecht, Amsterdam, Netherlands, 5MUmc, Amsterdam, Netherlands, 6Amsterdam University Medical Centers, Amsterdam, Netherlands, 7Amsterdam University Medical Center, Kortenhoef, Netherlands

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Comorbidity, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: We have documented that patients with rheumatoid arthritis (RA) are at increased risk to develop cardiovascular disease (CVD) compared to the general population, even after correction for traditional risk factors, a risk similar to that of patients with diabetes mellitus (DM). The objective of the current study was to extend our investigation to a follow up of more than 20 years, with a special focus on patients without prevalent CVD.

Methods: The CARRÉ study is an ongoing prospective cohort study on CV endpoints in 353 randomly selected patients with RA. Data was collected after three, ten, fifteen and twenty years of follow up. Results were compared to those of a reference cohort (n = 2484) enriched for type 2 DM. Primary focus was on patients without prevalent CVD at baseline. Hazard ratios for RA and DM patients compared to non-RA/-DM controls were calculated with cox proportional hazard models, and adjusted for baseline SCORE1 (a score that estimates 10-year risk of death due to CVD based on age, sex, smoking, systolic blood pressure and cholesterol levels).

Results: 238 RA patients, 117 DM patients and 1282 controls, all without prevalent CVD at baseline were included in primary analyses. The primary analysis of events in patients without prevalent CVD shows that after adjustment for SCORE1, no relevant ‘RA-specific’ risk is observed, whereas a ‘DM-specific’ risk is retained (Table 1, Figure 1). In contrast, analyses of all cases (as was done in prior reports of this cohort) confirms the presence of an ‘RA-specific’ risk of about 50% (Table 2).

Conclusion: This new analysis of our cohort, now with 20-year follow up, focuses on CVD risk in RA patients without prevalent CVD, and was facilitated by the use of the SCORE1. These patients have an increased risk that is mainly attributable to increased presence of traditional risk factors. After adjustment for these factors, an increased risk attributable to RA only was thus preferentially seen in the patients with prevalent CVD at baseline. As RA treatment has improved over the observation period, this data suggests that the ‘RA-specific’ effect of inflammation preferentially targets damaged vessels. We suggest that with modern (early) treatment of RA, most of the increased CVD risk is mediated through traditional risk factors.

Supporting image 1

Figure 1A-B: Cumulative hazard curves for cardiovascular events.
Right panel, hazard for rheumatoid arthritis (RA) and diabetes mellitus (DM) patients adjusted for
calculated SCORE1 results. Patients at risk shown are at the 5 and 15 year benchmarks.

Supporting image 2

Table 1: Incident CVD in RA patients and DM patients vs healthy controls without prevalent CVD
* Both fatal and nonfatal events.
Hazard ratios are shown with 95% confidence intervals. Results were adjusted for calculated SCORE1 results. RA = rheumatoid arthritis, DM = diabetes mellitus, CV = cardiovascular.

Supporting image 3

Table 2: Incident CVD in RA patients and DM patients vs healthy controls with prevalent CVD
* Both fatal and nonfatal events.
Hazard ratios are shown with 95% confidence intervals. Results were adjusted for calculated SCORE1 results. RA = rheumatoid arthritis, DM = diabetes mellitus, CV = cardiovascular.


Disclosures: R. Raadsen, None; R. Agca, None; M. Boers, Novartis; V. van Halm, None; M. Peters, None; Y. Smulders, None; J. Beulens, None; M. Blom, None; C. Stehouwer, None; A. Voskuyl, None; W. Lems, None; M. Nurmohamed, None.

To cite this abstract in AMA style:

Raadsen R, Agca R, Boers M, van Halm V, Peters M, Smulders Y, Beulens J, Blom M, Stehouwer C, Voskuyl A, Lems W, Nurmohamed M. In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/in-ra-patients-without-prevalent-cvd-incident-cvd-is-only-associated-with-traditional-risk-factors-a-20-year-follow-up-in-the-carre-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-ra-patients-without-prevalent-cvd-incident-cvd-is-only-associated-with-traditional-risk-factors-a-20-year-follow-up-in-the-carre-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology